With a strong foundation in corporate leadership and entrepreneurship, Andrew Blass has made significant contributions across various sectors. His expertise spans operations and strategic planning, leveraging his background to drive growth and innovation within organizations. Through effective management roles, he has cultivated teams that excel in execution while navigating complex market environments. Known for fostering relationships with stakeholders, his influence extends beyond traditional business parameters into investment circles where he identifies opportunities for advancement. Blass's commitment to excellence positions him as a notable figure at the intersection of strategy and finance.
With a strong foundation in corporate leadership and entrepreneurship, Andrew Blass has made significant contributions across various sectors. His expertise spans operations and strategic planning, leveraging his background to drive growth and innovation within organizations. Through effective management roles, he has cultivated teams that excel in execution while navigating complex market environments. Known for fostering relationships with stakeholders, his influence extends beyond traditional business parameters into investment circles where he identifies opportunities for advancement. Blass's commitment to excellence positions him as a notable figure at the intersection of strategy and finance.
With a keen eye for market dynamics, Andrew Blass consistently pursues investment opportunities that harness innovative strategies. His entrepreneurial mindset allows him to identify and capitalize on transformational growth areas across diverse sectors. By prioritizing operational efficiency and strategic foresight, he directs investments toward businesses with the potential for disruption and value creation. Emphasizing strong relationships with stakeholders enhances his ability to navigate competitive landscapes effectively while aligning interests across various parties. This approach underscores a commitment not only to capital appreciation but also to fostering lasting partnerships that drive sustained success.
With a keen eye for market dynamics, Andrew Blass consistently pursues investment opportunities that harness innovative strategies. His entrepreneurial mindset allows him to identify and capitalize on transformational growth areas across diverse sectors. By prioritizing operational efficiency and strategic foresight, he directs investments toward businesses with the potential for disruption and value creation. Emphasizing strong relationships with stakeholders enhances his ability to navigate competitive landscapes effectively while aligning interests across various parties. This approach underscores a commitment not only to capital appreciation but also to fostering lasting partnerships that drive sustained success.
| Trades 1433 | Longs Won 957/1433 66% | Profit Factor 6.01 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $493,136.71 |
| Average Win $55,692.55 | Best Trade (Oct 21) $18.74M | Sharpe Ratio -11.13 |
| Average Loss -$18,623.39 | Worst Trade (Mar 31) -$969,396.3 | Z-Score 11.84 (100%) |
| Commissions $0 | Avg. Trade Length 1y 6m 2d | Expectancy $31,007 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% | 1.38% |
| Consecutive Losing Trades | 8,547 | 7,692 | 6,838 | 5,983 | 5,128 | 4,274 | 3,419 | 2,564 | 1,709 | 855 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AA Alcoa Corporation | 5 | $265.7 | $190.9 | - | -$74.8 | -28.15% | -1.344% |
AAPL Apple Inc. | 2,969 | $700,322.6 | $1.03M | - | $327,367.06 | 46.75% | -0.597% |
ABBV AbbVie Inc. | 12 | $2,778.48 | $3,429.9 | - | $651.42 | 23.45% | +0.223% |
ABT Abbott Laboratories | 250 | $28,502.5 | $25,812.5 | - | -$2,690 | -9.44% | +0.722% |
ACGL Arch Capital Group Ltd. | 400 | $44,752 | $40,672 | - | -$4,080 | -9.12% | -0.984% |
ADI Analog Devices, Inc. | 100 | $23,017 | $38,932.77 | - | $15,915.77 | 69.15% | +0.925% |
ADPT Adaptive Biotechnologies Corporation Common Stock | 3.75 | $243.6 | $94.84 | - | -$148.76 | -61.07% | +3.605% |
ALNY Alnylam Pharmaceuticals, Inc. | 1 | $397.65 | $227.84 | - | -$169.81 | -42.7% | +0.246% |
AMAT Applied Materials Inc. | 250 | $50,512.5 | $95,040 | - | $44,527.5 | 88.15% | +1.219% |
AMD Advanced Micro Devices Inc. | 65 | $13,920.4 | $33,491.25 | - | $19,570.85 | 140.59% | +1.441% |
AME AMETEK, Inc. | 123 | $17,875.59 | $29,542.75 | - | $11,667.16 | 65.27% | +0.572% |
AMGN Amgen Inc. Common Stock | 3 | $981.93 | $1,323.9 | - | $341.97 | 34.83% | -1.337% |
AMRX Amneal Pharmaceuticals, Inc. | 20 | $252 | $405.2 | - | $153.2 | 60.79% | -1.074% |
AMZN Amazon.com Inc | 370 | $75,826.83 | $92,204 | - | $16,377.17 | 21.6% | -0.471% |
ANET Arista Networks Inc. | 5 | $655.15 | $864.85 | - | $209.7 | 32.01% | +1.111% |
APA APA Corporation | 10 | $244.6 | $516.8 | - | $272.2 | 111.28% | +4.531% |
APH Amphenol Corp. Class A Common Stock | 112 | $2,765.06 | $8,305.92 | - | $5,540.86 | 200.39% | +1.492% |
ARVN Arvinas, Inc. | 577 | $14,211.51 | $4,194.79 | - | -$10,016.72 | -70.48% | -5.829% |
ARWR Arrowhead Pharmaceuticals, Inc. | 2,600 | $50,362 | $150,514 | - | $100,152 | 198.86% | -0.805% |
ASML ASML Holding N.V. NY Registered Shares | 117 | $134,205.81 | $184,068.49 | - | $49,862.68 | 37.15% | +0.813% |